Biomarkers for selecting biologic therapies in asthma - PubMed
a day ago
- #biomarkers
- #biologic-therapies
- #asthma
- Asthma is a heterogeneous chronic respiratory disease with diverse inflammatory pathways.
- Biologic therapies have transformed the management of moderate-to-severe asthma.
- Selecting the appropriate biologic therapy remains challenging, often relying on trial-and-error approaches.
- Biomarkers are essential for precision asthma care, providing objective measures of disease mechanisms.
- Established biomarkers include blood eosinophil count, fractional exhaled nitric oxide, and serum total immunoglobulin E.
- Sputum biomarkers offer direct insight into airway inflammation but are limited by technical complexity.
- Emerging biomarkers include proteomic, transcriptomic, metabolomic, and genomic biomarkers.
- Digital biomarkers from electronic health records and wearable devices offer new opportunities.
- Socioeconomic factors are recognized as modifiers of biologic effectiveness.
- Integrating multiple biomarkers is essential for improving biologic selection and achieving remission in asthma.